BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

744 related articles for article (PubMed ID: 26191276)

  • 1. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DEF6 expression in ovarian carcinoma correlates with poor patient survival.
    Liew PL; Fang CY; Lee YC; Lee YC; Chen CL; Chu JS
    Diagn Pathol; 2016 Aug; 11(1):68. PubMed ID: 27488395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival.
    Cho HY; Kim K; Kim YB; Kim H; No JH
    Int J Gynecol Cancer; 2017 Mar; 27(3):412-419. PubMed ID: 28129239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
    Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
    Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer.
    Bodnar L; Stanczak A; Cierniak S; Smoter M; Cichowicz M; Kozlowski W; Szczylik C; Wieczorek M; Lamparska-Przybysz M
    J Ovarian Res; 2014 Feb; 7():16. PubMed ID: 24499657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression.
    Bi R; Shen X; Zhang W; Cheng Y; Feng Z; Cai X; Yang W
    Diagn Pathol; 2016 Feb; 11():17. PubMed ID: 26837693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear β-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer.
    Nagy B; Tóth L; Molnár P; Méhes G; Thurzó L; Póka R; Hernádi Z
    Pathol Res Pract; 2017 Aug; 213(8):915-921. PubMed ID: 28651933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer.
    Skirnisdottir I; Seidal T
    Cancer Genomics Proteomics; 2013; 10(1):27-34. PubMed ID: 23382584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
    Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.
    Kari E; Teppo HR; Haapasaari KM; Kuusisto MEL; Lemma A; Karihtala P; Pirinen R; Soini Y; Jantunen E; Turpeenniemi-Hujanen T; Kuittinen O
    J Clin Pathol; 2019 Apr; 72(4):316-321. PubMed ID: 30755497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phospho-histone H2AX is a diagnostic and prognostic marker for epithelial ovarian cancer.
    Mei L; Hu Q; Peng J; Ruan J; Zou J; Huang Q; Liu S; Wang H
    Int J Clin Exp Pathol; 2015; 8(5):5597-602. PubMed ID: 26191270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.
    Voutilainen KA; Anttila MA; Sillanpää SM; Ropponen KM; Saarikoski SV; Juhola MT; Kosma VM
    J Clin Pathol; 2006 May; 59(5):460-7. PubMed ID: 16461565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Keap1 expression has independent prognostic value in pancreatic adenocarcinomas.
    Isohookana J; Haapasaari KM; Soini Y; Karihtala P
    Diagn Pathol; 2015 Apr; 10():28. PubMed ID: 25879528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma.
    Zhang H; Liu J; Yue D; Gao L; Wang D; Zhang H; Wang C
    J Clin Pathol; 2013 Nov; 66(11):937-45. PubMed ID: 23853314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased BTB-Kelch type substrate adaptor protein immunoreactivity associates with advanced stage and poor differentiation in renal cell carcinoma.
    Ronkainen H; Vaarala MH; Kauppila S; Soini Y; Paavonen TK; Rask J; Hirvikoski P
    Oncol Rep; 2009 Jun; 21(6):1519-23. PubMed ID: 19424632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.